Screening breast, ovarian cancer gene mutations other than BRCA1/2 impact management

the ONA take:

Multigene testing for hereditary breast and/or ovarian cancer that tests for more gene mutations than BRCA1/2 is more likely to inform clinical decision-making than testing for BRCA1/2 alone, according to a new study published online ahead of print in JAMA Oncology.

"The traditional approach has been to test most women with suspected hereditary risk for breast and/or ovarian cancer for BRCA1/2 alone," senior author Leif Ellisen, MD, PhD, program director for Breast Medical Oncology at the MGH Cancer Center said.

Of 1,046 study participants, 40 BRCA1/2-negative patients harbored deleterious mutations. The most common mutations were in CHECK2, ATM, PALB2, and Lynch syndrome genes. Researchers found that for the majority those and an additional 23 mutation-positive patients their clinics, additional disease-specific screening and/or prevention measures other than those based on personal and family history alone would be considered.

"Our study shows that, even under current practice guidelines, finding mutations in these other genes is likely to change the clinical management recommendations both for patients and for family members who also carry the associated mutations," explains Dr. Ellisen.

Screening breast, ovarian cancer gene mutations other than BRCA1/2 will impact clinical management
Multigene testing for hereditary breast and/or ovarian cancer that tests is more likely to inform clinical decision-making than testing for BRCA1/2 alone.
A study by researchers at three academic medical centers has shown that screening women with a suspected risk of hereditary breast or ovarian cancer for risk-associated genes other than BRCA1 and 2 provides information that can change clinical recommendations for patients and their family members.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs